Tonix Pharmaceuticals Holding short interest in 2020
In 2020, Tonix Pharmaceuticals Holding's disclosed short interest ran from 3.80% of shares outstanding on 31 Mar 2020 to 0.37% on 15 Dec 2020, a change of -3.43 percentage points. The year's high was 5.84% on 31 Jul 2020 and its low 0.28% on 30 Nov 2020, averaging 1.66% across 18 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 1.00 days on 31 Mar 2020. Full history: Tonix Pharmaceuticals Holding.
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2025 · 2026
2020 in figures
- Start of year
- 3.80% (31 Mar 2020)
- End of year
- 0.37% (15 Dec 2020)
- Change
- -3.43 pp
- High
- 5.84% (31 Jul 2020)
- Low
- 0.28% (30 Nov 2020)
- Average
- 1.66%
- Highest days to cover
- 1.00 (31 Mar 2020)
- SEC filings marked
- 8
Every report in 2020
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 31 Mar 2020 | 3.80% | 1.00 | 10-K filed, results (8-K) |
| 15 Apr 2020 | 1.58% | 1.00 | |
| 30 Apr 2020 | 0.80% | 1.00 | |
| 15 May 2020 | 1.89% | 1.00 | 10-Q filed, results (8-K) |
| 29 May 2020 | 1.04% | 1.00 | |
| 15 Jun 2020 | 1.52% | 1.00 | |
| 30 Jun 2020 | 3.07% | 1.00 | |
| 15 Jul 2020 | 2.92% | 1.00 | |
| 31 Jul 2020 | 5.84% | 1.00 | |
| 14 Aug 2020 | 1.42% | 1.00 | 10-Q filed, results (8-K) |
| 31 Aug 2020 | 1.18% | 1.00 | |
| 15 Sep 2020 | 1.48% | 1.00 | |
| 30 Sep 2020 | 0.76% | 1.00 | |
| 15 Oct 2020 | 0.74% | 1.00 | |
| 30 Oct 2020 | 0.60% | 1.00 | |
| 13 Nov 2020 | 0.51% | 1.00 | 10-Q filed, results (8-K) |
| 30 Nov 2020 | 0.28% | 1.00 | |
| 15 Dec 2020 | 0.37% | 1.00 |
See also: Tonix Pharmaceuticals Holding's full history · most shorted US stocks of 2020 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.